Pacific Biosciences of California (NASDAQ: PACB) revenue
Pacific Biosciences of California reported revenue of $160.0m for fiscal 2025, 3.9% more than in fiscal 2024 ($154.0m). Since fiscal 2016 its revenue has grown by 76.4%, an average growth of 6.5% a year.
Pacific Biosciences of California's best year of the last 10 was fiscal 2023. The biggest drop was in fiscal 2024, −23.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $160.0m | +3.9% | −$553.9m | −346.2% |
| 2024 | $154.0m | −23.2% | −$474.3m | −308.0% |
| 2023 | $200.5m | +56.3% | −$334.5m | −166.8% |
| 2022 | $128.3m | −1.7% | −$307.2m | −239.4% |
| 2021 | $130.5m | +65.4% | −$210.4m | −161.2% |
| 2020 | $78.9m | −13.2% | −$104.4m | −132.3% |
| 2019 | $90.9m | +15.6% | −$100.5m | −110.6% |
| 2018 | $78.6m | −15.9% | −$101.0m | −128.4% |
| 2017 | $93.5m | +3.0% | −$89.8m | −96.1% |
| 2016 | $90.7m | — | −$71.2m | −78.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Pacific Biosciences of California revenue compared with its sector
By revenue for its latest fiscal year, Pacific Biosciences of California ranks 259th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Pacific Biosciences of California, 3.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 257th | Regenxbio | $170.4m | 104.5% |
| 258th | Ginkgo Bioworks | $170.2m | −25.1% |
| 259th | Pacific Biosciences of California | $160.0m | 3.9% |
| 260th | Liquidia | $158.3m | 1,031.2% |
| 261st | Heron Therapeutics | $154.9m | 7.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Pacific Biosciences of California
- How much revenue did Pacific Biosciences of California make in fiscal 2025?
- Pacific Biosciences of California reported revenue of $160.0m for fiscal 2025, compared with $154.0m in fiscal 2024.
- How much has the revenue of Pacific Biosciences of California grown?
- Between fiscal 2016 and fiscal 2025 it went from $90.7m to $160.0m: 76.4% more, an average growth of 6.5% a year.
- What was the best year for revenue at Pacific Biosciences of California?
- Of its last 10 fiscal years, fiscal 2023, with $200.5m.
- Where does Pacific Biosciences of California rank in its sector by revenue?
- It ranks 259th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Pacific Biosciences of California come from?
- From the annual report (Form 10-K) that Pacific Biosciences of California files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Pacific Biosciences of California files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Pacific Biosciences of California: the Pacific Biosciences of California page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.